Incannex Healthcare Limited
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Joel Bradley Latham
- Full Time Employees
- 12
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 207/11 Solent Circuit Sydney NSW Australia 2153
- IPO Date
- Mar 2, 2022
- CIK
- 0001873875
- Website
- incannex.com
- Similar Companies
- Business
- Incannex Healthcare Inc. (Nasdaq: IXHL) operates as a clinical-stage biopharmaceutical company focused on researching, developing, and commercializing novel oral fixed-dose combination medicines and psychedelic-assisted therapies targeting chronic conditions with significant unmet medical needs, including obstructive sleep apnea, rheumatoid arthritis, inflammatory bowel disease, lung inflammation, and generalized anxiety disorder; its lead product candidates include IHL-42X, an oral fixed-dose combination of dronabinol and acetazolamide in Phase 2/3 clinical trials (RePOSA program) for obstructive sleep apnea by addressing intermittent hypoxia and hypercapnia through synergistic physiological pathways, IHL-675A, an oral fixed-dose combination of synthetic cannabidiol and hydroxychloroquine sulfate in Phase 2 clinical trials for rheumatoid arthritis, inflammatory lung conditions such as chronic obstructive pulmonary disease and asthma, acute respiratory distress, bronchitis, colitis, and Crohn's disease via dual anti-inflammatory mechanisms, and PSX-001 (PsiGAD), an oral synthetic psilocybin formulation administered with psychotherapy in Phase 2b clinical development for generalized anxiety disorder. Founded in 2001 and headquartered in Sydney, Australia (with prior references to Docklands and Melbourne operations), the company holds an Australian license authorizing the import, export, and distribution of medicinal cannabis products and conducts all activities through a single research and development segment, primarily serving patients and healthcare providers in Australia while pursuing U.S. regulatory approvals and global expansion. Recent developments include a $16.7 million capital raise completed in May 2025 to cancel Series A warrants, reduce potential shareholder dilution, and support advancement of its pipeline with preliminary IHL-42X Phase 2/3 results expected in July 2025; a strategic financing agreement in September 2024 providing up to $10 million in convertible notes and a $50 million equity line of credit from Arena Investors LP and affiliates to fund late-stage trials; and a $12.5 million private placement in May 2025 alongside a 33% reduction in general and administrative expenses to strengthen its balance sheet amid industry consolidation, with additional focus on partnerships such as a joint venture with Mind Medicine Australia for psychedelic therapies.
Company News
Incannex Announces First Patient Dosed in DReAMzz Phase 2 Study of IHL-42X
Incannex Commences Participant Screening in DReAMzz Phase 2 Study of IHL-42X for Obstructive Sleep Apnea
Incannex Secures U.S. Patent Grant for IHL-42X in Obstructive Sleep Apnea
Incannex Receives A$6.0 Million R&D Tax Incentive Refund for FY25, Further Strengthening Balance Sheet and Financial Flexibility
Incannex Receives A$6.0 Million R&D Tax Incentive Refund for FY25, Further Strengthening Balance Sheet and Financial Flexibility
Incannex Announces Initiation of Research Coverage by Alliance Global Partners
Incannex Healthcare Officially Commences DReAMzz Clinical Study for IHL-42X in Obstructive Sleep Apnea
Incannex Healthcare Wins MedTech Breakthrough Award for IHL-42X, Underscoring Leadership in Next-Generation Drug Development
Incannex Healthcare Recognized for Innovative Drug Development Solutions by MedTech Breakthrough
Incannex Healthcare (NASDAQ:IXHL) and Cronos Group (NASDAQ:CRON) Financial Contrast
Incannex Healthcare PSX-001 Program Aligns with White House Executive Order Accelerating Access to Psychedelic Treatments for Serious Mental Illness
Incannex Reactivates Share Repurchase Program, Underscoring Confidence in Valuation and Strategic Position
Incannex Healthcare Announces Partnership with the AASM Foundation in Support of Sleep Apnea Research
Incannex Highlights Strong Balance Sheet with Approximately $75 Million in Cash and No Debt as Company Advances IHL-42X Development
Incannex Regains Compliance with Nasdaq Minimum Bid Price Requirement
Incannex Stock Slides As $10 Million Capital Raise Funds Next Study For Sleep Apnea Treatment
Incannex Healthcare Inc. Announces Pricing of $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Incannex Announces Reverse Stock Split
Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 2Q 2026
Incannex Healthcare Announces Additional Appointments to Clinical Advisory Board